Peptide

Rebound nach GLP-1Studienlage & Dosis

Gewichtszunahme nach Absetzen ohne Lifestyle-Anker.

Studienlage in Zahlen

Studien gesamt: 251
Mit Abstract: 50
Meta / Systematic / RCT: 1
Häufig zitiert: 50
Erscheinungsjahre: 1996–2026

Rebound nach GLP-1 im Kontext von Peptide

Dieses Thema ist Teil unserer Welt „Peptide". Dort findest du Methodik, Studienlage und Hebel mit dem größten Effekt — sowie die Reihenfolge, in der sich Hebel sinnvoll aufeinander aufbauen.

Zur Welt Peptide

Top-Studien zu Rebound nach GLP-1

Sortiert nach einflussreichen Zitationen und Erscheinungsjahr.

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial.
JAMA2008n=60200 einflussreiche Zitationen
<h4>Context</h4>Observational studies suggest that surgically induced loss of weight may be effective therapy for type 2 diabetes.<h4>Objective</h4>To determine if surgically induced weight loss results in better glycemic control and less…
Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism2008n=10147 einflussreiche Zitationen
<h4>Context</h4>Gastric bypass surgery (GBP) results in rapid weight loss, improvement of type 2 diabetes (T2DM), and increase in incretins levels. Diet-induced weight loss also improves T2DM and may increase incretin…
Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial.
Obesity surgery2012n=100138 einflussreiche Zitationen
<h4>Background</h4>The mechanisms of amelioration of glycemic control early after laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) are not fully understood.<h4>Methods</h4>In this prospective,…
The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism.
Annals of surgery2004118 einflussreiche Zitationen
<h4>Objective</h4>To evaluate the early effect of Roux-en-Y (RYGB) gastric bypass on hormones involved in body weight regulation and glucose metabolism. SIGNIFICANT BACKGROUND DATA: The RYGB is an effective bariatric procedure for which…
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
Journal of clinical medicine202591 einflussreiche Zitationen
<b>Objectives:</b> The primary objective of this review is to analyze the effects on body weight of discontinuing therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or tirzepatide in patients treated for obesity. In recent…
Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass.
International journal of obesity (2005)2009n=2878 einflussreiche Zitationen
<h4>Objective</h4>The objective of this study was to quantify hormones that regulate energy and glucose homeostasis to establish possible mechanisms for the greater efficacy of Roux-en-Y gastric bypass (RYGB) compared with laparoscopic…
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Obesity reviews : an official journal of the International Association for the Study of Obesity201976 einflussreiche Zitationen
Summary We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the context of obesity and type 2 diabetes, may improve glycaemic control and weight‐related comorbidities, and in some cases, induce diabetes…
The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery2017n=5.11071 einflussreiche Zitationen
<h4>Background</h4>Patients who undergo bariatric surgery often have inadequate weight loss or weight regain.<h4>Objectives</h4>We sought to discern the utility of weight loss pharmacotherapy as an adjunct to bariatric surgery in patients…
Rational design of a combination medication for the treatment of obesity.
Obesity (Silver Spring, Md.)200966 einflussreiche Zitationen
Existing obesity therapies are limited by safety concerns and modest efficacy reflecting a weight loss plateau. Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid…
Gastric bypass and banding equally improve insulin sensitivity and β cell function.
The Journal of clinical investigation201265 einflussreiche Zitationen
Bariatric surgery in obese patients is a highly effective method of preventing or resolving type 2 diabetes mellitus (T2DM); however, the remission rate is not the same among different surgical procedures. We compared the effects of 20%…

Häufige Fragen

Welche Dosierung wurde in den Studien untersucht?

• laparoscopic adjustable gastric banding with conventional diabetes care

Weitere Themen in Peptide

Peptide-Überblick

Peptide, BPC-157, TB-500, Sicherheit und Studienlage.

Verabreichung

Subkutan, intramuskulär, nasal, oral, topisch — Bioverfügbarkeit und Sicherheit.

Autoimmunitäts-Risiko

Immun-Modulation kann sowohl Toleranz fördern als auch entgleisen lassen.

BPC-157

Peptid für Geweberegeneration, Heilung und sportliche Erholung.

Cerebrolysin

Schweinehirn-Peptid-Mix, Schlaganfall-Studien, in DE unzugelassen.

CJC-1295

GHRH-Analog, Halbwertszeit-Varianten und Pulse-Patterns.

Dihexa

Angiotensin-Derivat, kognitive/Neuroplastizitäts-Hinweise im Tiermodell.

GHK-Cu

Kupfer-Peptid für Hautgesundheit, Anti-Aging und Wundheilung.

GHRP-2

GH-Releaser, älter, Appetit-Stimulation als Nebeneffekt.

GHRP-6

GH-Releaser mit starker Appetit-Komponente.

GLP-1 Nebenwirkungen

Übelkeit, Magenentleerung, Muskelverlust, Pankreatitis-Risiko.

Hexarelin

GH-Releaser, Toleranz-Aufbau schnell, kardiale Hinweise.

IGF-1 LR3

Modifiziertes IGF-1 mit langer Halbwertszeit — Hypertrophie, Krebsrisiko-Debatte.

Immune Modulation

Automatisch via Trend Scout entdeckt. Supplements targeting inflammation and immune resilience remain a central research area.. PubMed: 11956 Ergebnisse.

Injektionssicherheit

Sterile Technik, BAC-Wasser, Hautdesinfektion — medizinisches Thema.

Ipamorelin

Selektiver GH-Releaser, Cortisol-Sparing und Stack-Kombinationen.

KPV

Alpha-MSH-Fragment — entzündungshemmend, Darm, Haut, frühe Forschung.

Liraglutid

Erste GLP-1-Generation für Diabetes/Adipositas — täglich, niedrigere Effektgröße.

LL-37

Antimikrobielles Peptid, Wundheilung, Immun-Modulation, frühe Forschung.

MK-677

Ghrelin-Mimetikum, kein Peptid streng genommen — Schlaf, Appetit, Glukose-Risiko.